Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Incyte (INCY -7.9%) slips today after disclosing that a UK patient taking its bone-marrow drug Jakafi died of a rare brain infection. The company says it's unclear whether Jakafi caused the infection and that it's the only reported case among nearly 10K people who've taken the drug. [View news story]
    Talk about an over reaction by the market. PML can be caused by multiple things and it's highly unlikely that a direct causation would happen after 10,000 patients being treated.
    Mar 18, 2013. 12:03 PM | Likes Like |Link to Comment
  • Eli Lilly (LLY) and Incyte (INCY) announce positive results from ongoing Phase IIb studies of baricitinib in patients with rheumatoid arthritis who had an inadequate response to treatment with methotrexate. Additionally, MRI technology was used in a sub-study to examine the effect of baricitinib on joint erosion and other markers of structural changes in and around the joint, which showed statistically significant improvement in both the Total Inflammation Score and the Total Joint Damage Score compared with placebo at 12 weeks. LLY +0.8%, INCY -0.9% AH. [View news story]
    Any clue why Incyte would drop? Seems the market does not like this company.
    Nov 14, 2012. 04:39 AM | Likes Like |Link to Comment
  • Annaly (NLY) CFO Kathryn Fagan exercises options to purchase 37.5K shares of company stock at $13.25 each, upping her stake in the company by nearly 15% to 290.5K shares. This follows purchases last week by the CEO and CIO.  [View news story]
    Seems like someone knows something
    Apr 30, 2012. 07:07 PM | Likes Like |Link to Comment